Zobrazeno 1 - 10
of 199
pro vyhledávání: ''
Publikováno v:
Saudi Journal of Biological Sciences, Vol 29, Iss 1, Pp 513-520 (2022)
Saudi Journal of Biological Sciences
Saudi Journal of Biological Sciences
Background and objectives Peptic ulcer disease, chronic gastritis, and stomach cancer are all caused by H. pylori. The most notable drug for the treatment is the antibiotic clarithromycin, which is currently the drug of choice. H. pylori clarithromyc
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 27, Iss, Pp 67-71 (2021)
Objectives The objective of this study was to evaluate the efficacy of different dosing regimens of ceftazidime/avibactam (CZA) in patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) pulmonary infections. Methods A tota
Publikováno v:
Medical Mycology Case Reports, Vol 34, Iss, Pp 18-21 (2021)
Medical Mycology Case Reports
Medical Mycology Case Reports
To our knowledge, this is the first case report of a transudative pleural effusion with positive Cryptococcal antigen and culture. We describe a 32-year-old male with end-stage liver disease (ESLD) who presented to an outside hospital with dyspnea an
Autor:
Matteo Rinaldi, Cristina Crovara Pesce, Maddalena Giannella, Paolo Gaibani, Simone Ambretti, Donatella Lombardo, Federico Pea, Pierluigi Viale, Milo Gatti, Stefano Amadesi, Tiziana Lazzarotto
Publikováno v:
International Journal of Infectious Diseases, Vol 113, Iss, Pp 213-217 (2021)
Objectives Ceftazidime-avibactam (CAZ-AVI) is a promising novel agent with activity against carbapenem-resistant Enterobacteriaceae. Here, we describe the dynamic evolution of a Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC
Autor:
Khaled Nauman, Abdullah N. Al Jurayyan, Meshari A. Almosallam, Salah Alahmedi, Muhammad Zubair Siddiqi, Jamal M. Khaled, Ahmed S. Alobaidi, Naiyf S. Alharbi, Abeer O. Almazyed
Publikováno v:
Journal of Infection and Public Health, Vol 14, Iss 11, Pp 1679-1685 (2021)
Background: The upgrowth and rapid prevalence of pandrug-resistant Acinetobacter baumannii strains that have a pathogenic activity to cause several infections are of considerable influence on the health of communities worldwide. No infections by thes
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 26, Iss, Pp 207-218 (2021)
Objectives Globally, tuberculosis (TB) incidence and mortality are declining; however, low detection of drug-resistant disease threatens to reverse current progress toward global TB control. Multiple, rapid molecular diagnostic tests have recently be
Autor:
Hasanthi Vallabhaneni, Brianna Garza, Lizbeth Cahuayme-Zuniga, John K. Midturi, Ryan Beaver, Tiffany LaDow
Publikováno v:
Medical Mycology Case Reports, Vol 33, Iss, Pp 21-25 (2021)
Medical Mycology Case Reports
Medical Mycology Case Reports
The standard of care for treatment of sino-orbital mucormycosis involves aggressive surgical debridement and liposomal amphotericin, and the roles of adjunctive and topical therapies are less clear. Here we describe a case of severe refractory sino-o
Autor:
Qiwen Yang, Jingjia Zhang, Yingchun Xu, Ge Zhang, Simeng Duan, Yang Yang, Dongxue Li, Hui Zhang
Publikováno v:
Journal of Microbiology, Immunology and Infection, Vol 54, Iss 4, Pp 639-648 (2021)
Background We describe antibiotic resistance trends of Klebsiella pneumoniae pathogens, responsible for urinary tract infections (UTIs) and intra-abdominal infections (IAIs), isolated from different organs and tissues, hospital departments and Chines
Publikováno v:
Journal of Microbiology, Immunology and Infection, Vol 54, Iss 4, Pp 575-580 (2021)
Background Necrotizing enterocolitis (NEC) is one of the most serious complications in preterm infants. Probiotics have been used to prevent NEC. Safety is a major concern for this practice. Methods We reported a female preterm infant who received or
Publikováno v:
Medical Mycology Case Reports, Vol 32, Iss, Pp 77-80 (2021)
Mucorales infections in cetaceans have a high mortality rate. This case report refers to a bottlenose dolphin calf with suspected mucormycosis treated with posaconazole. This antifungal agent was discontinued after 96 days of therapy, however, the in